SNP, Allele | Patients Who Did Not Discontinue MTX Because of AE, n = 110 | Patients Who Discontinued MTX Because of AE, n = 7 |
---|---|---|
Folate pathway | ||
RFC1 rs1051266, C | 72 | 43 |
MTHFR rs1801133, T | 61 | 29 |
MTHFR rs1801131, C | 53 | 100 |
MTR rs1805087, G | 32 | 0 |
MTRR rs1801394, G | 86 | 100 |
MTHFD1 rs2236225, A | 68 | 71 |
TYMS rs34743033, 3R | 77 | 57 |
Adenosine pathway | ||
ATIC rs2372536, G | 59 | 71 |
AMPD1 rs17602729, A | 25 | 14 |
MTX transporters | ||
ABCG2 rs2231142, T | 23 | 14 |
ABCG2 rs2231137, T | 71 | 0 |
ABCC2 rs717620, T | 41 | 29 |
ABCC2 rs2804402, G | 82 | 86 |
ABCC2 rs2273697, A | 41 | 0 |
ABCB1 rs1045642, G | 72 | 71 |
SLCO1B1 rs11045879, C | 37 | 57 |
Significant data are in bold face. MTX: methotrexate; AE: adverse events; SNP: single-nucleotide polymorphism.